Biophage signs a MOU with two US Companies for developing new generation of PDS® biosensors
Biophage Pharma Inc. announced that it has signed a memorandum of understanding with two U.S. companies, Indus Instruments, and International Science Consulting, LLC (ISC), for the development and manufacturing of the a new generation of PDS® biosensors.
Under this MOU, Indus and ISC will develop for Biophage proprietary equipment for the detection of live bacterial pathogens and their toxins. As compensation, Indus and ISC will receive US$50,000 and 3,800,000 non-transferable warrants, each such warrant entitling the holder thereof to purchase one common share of the capital of Biophage at any time, for a period of two years after the date of its grant. Out of the 3,800,000 abovementioned warrants, 2,800,000 will be exercisable at a price of CAN$0.12 and 1,000,000 will be exercisable at a price of CAN$0.30. The parties have agreed to enter into a more detailed development agreement.
Most read news
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.